Cargando…
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
BACKGROUND: CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity. METHODS: This phase I dose-escalation study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of CYT997 administered by continuous intravenous infusi...
Autores principales: | Lickliter, J D, Francesconi, A B, Smith, G, Burge, M, Coulthard, A, Rose, S, Griffin, M, Milne, R, McCarron, J, Yeadon, T, Wilks, A, Cubitt, A, Wyld, D K, Vasey, P A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938266/ https://www.ncbi.nlm.nih.gov/pubmed/20733579 http://dx.doi.org/10.1038/sj.bjc.6605841 |
Ejemplares similares
-
Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity
por: Teng, Yong, et al.
Publicado: (2017) -
Intracellular reduction in ATP levels contributes to CYT997‐induced suppression of metastasis of head and neck squamous carcinoma
por: Zhao, Xiangdong, et al.
Publicado: (2018) -
CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma
por: Wang, Zongyi, et al.
Publicado: (2019) -
Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer
por: Cao, Ya, et al.
Publicado: (2020) -
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins
por: CHEN, XIAOHUI, et al.
Publicado: (2013)